CCM
CORT icon

Catalio Capital Management’s Corcept Therapeutics CORT Stock Holding History

Catalio Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-239,125
Closed -$17.6M – 39
2025
Q2 		$17.6M Buy
+239,125
New +$17.3M 3.68% 12

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Catalio Capital Management's CORT Position: Q3 2025 in Review

Catalio Capital Management sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 239,125 shares — an estimated $17.6M sold.

Catalio Capital Management first reported a position in CORT in Q2 2025 and held it in 1 quarter. The position peaked at $17.6M in Q2 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • Catalio Capital Management reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Catalio Capital Management sold 239,125 Corcept Therapeutics shares in Q3 2025, an estimated $17.6M.
  • Catalio Capital Management first reported a position in Corcept Therapeutics in Q2 2025 and held it in 1 quarter.
  • Catalio Capital Management's Corcept Therapeutics position peaked at $17.6M in Q2 2025.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Catalio Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.